Advancing BNCT

An emerging precision medicine modality to treat solid tumors

about BNCT

BNCT holds the potential to overcome poor survival rates for patients with a variety of cancers

Boron neutron capture therapy (BNCT) was initially conceived in the early 20th century. Due to recent advances in boron medicinal chemistry and targeted delivery of safe neutrons, the technology has shown great promise for treating patients with solid tumors.


Boron medicines are administered intravenously


Boron medicines preferentially accumulate in tumor cells


Tumor is precisely irradiated with safe, low-energy neutrons


Interaction of safe neutrons with boron medicines releases alpha particles that selectively destroy the tumor

The Future of BNCT

Learn how we are working with our partners Neutron Therapeutics and Leo Cancer Care to advance BNCT.

The nuBeam® system is currently in development and has not received US marketing authorization from the FDA.

A potentially safe, efficacious and convenient treatment option

Boron neutron capture therapy has been approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for unresectable advanced or recurrent head and neck cancer. Additional clinical research on BNCT is being conducted at 16 BNCT treatment centers worldwide.

The BNCT Ecosystem

To advance BNCT, we are building on generations of innovations in medicinal chemistry, neutron research and biopharmaceutical drug development. Through partnerships with biopharma companies and academic medical centers, we are working to expand access to this promising modality and establish U.S.-based BNCT treatment centers.